Long-term (68 weeks) administration of nemolizumab and topical corticosteroids for prurigo nodularis in patients aged ≥ 13 years: efficacy and safety data from a phase II/III study

This is the authors' abstract. We don't add key points for this paper.

Nemolizumab elicited continuous and durable improvements across multiple measures of pruritus, PN severity and QoL over 68 weeks of treatment, with no new safety concerns.